XLRN - Acceleron reports preliminary sotatercept data from mid-stage SPECTRA trial in PAH

Acceleron Pharma (XLRN) presents preliminary interim data from the SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension ((PAH)).The trial shows that sotatercept-treated patients  experienced improvements in multiple key hemodynamic measures. In this study, a total of 21 patients with advanced PAH on stable combination background therapy are to be treated with an initial cycle of 0.3 mg/kg of sotatercept delivered subcutaneously, followed by subsequent cycles of 0.7 mg/kg of sotatercept through a 24-week treatment period. As measured by invasive cardiopulmonary exercise testing (iCPET) at baseline and at week 24, investigators recorded improvements in peak oxygen uptake or VO2 max (the primary endpoint) as well as in a range of secondary endpoints, including ventilatory efficiency, total workload, and arteriovenous oxygen content.Improvements in resting hemodynamics were associated with sotatercept which included, reductions in pulmonary vascular resistance from a mean of 576 at baseline to 369 at week 24 (35.9% reduction)

For further details see:

Acceleron reports preliminary sotatercept data from mid-stage SPECTRA trial in PAH